NINA THU NGUYEN
Nail Technician in Houston, TX
License number
Pennsylvania CL007520R
Category
Cosmetology
Type
Nail Technician
Address
Address
2
Houston, TX 77072
Pennsylvania
Pennsylvania
Professional information
Nina Nguyen, Houston TX - CRNA (Certified registered nurse anesthetist)
Specialties:
Nurse Anesthesiology
Address:
1515 Holcombe Blvd, Houston 77030
(713) 834-6520 (Phone)
(713) 834-6520 (Phone)
Languages:
English
Hospitals:
1515 Holcombe Blvd, Houston 77030
The University of Texas M.D. Anderson Cancer Center
1515 Holcombe Blvd, Houston 77030
The University of Texas M.D. Anderson Cancer Center
1515 Holcombe Blvd, Houston 77030
Nina Nguyen, Houston TX
Specialties:
Nurse Practitioner
Address:
1515 Holcombe Blvd, Houston, TX 77030
14-3-3 Zeta Over-Expression As A Poor Prognosis Factor, And A Therapeutic Target In Multiple Cancer Type
US Patent:
7709205, May 4, 2010
Filed:
Dec 4, 2007
Appl. No.:
11/950264
Inventors:
Dihua Yu - Houston TX, US
Jun Yao - Chestnut Hill MA, US
Christopher L. Neal - Houston TX, US
Wentao Yang - Shanghai, CN
Xiaoyan Zhou - Shanghai, CN
Raphael E. Pollock - Houston TX, US
Mien-Chie Hung - Houston TX, US
Jun Yang - Houston TX, US
Ping Li - Houston TX, US
Nina T. Nguyen - Houston TX, US
Jun Yao - Chestnut Hill MA, US
Christopher L. Neal - Houston TX, US
Wentao Yang - Shanghai, CN
Xiaoyan Zhou - Shanghai, CN
Raphael E. Pollock - Houston TX, US
Mien-Chie Hung - Houston TX, US
Jun Yang - Houston TX, US
Ping Li - Houston TX, US
Nina T. Nguyen - Houston TX, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
Methods of determining prognosis in a subject with a hyperproliferative disease, including determining expression and/or function of 14-3-3 zeta in the subject, are disclosed. Also disclosed are methods of making a pharmaceutical agent that modulates apoptosis, including the steps of obtaining one or more candidate, testing the one or more candidate substances to determine their ability to modulate the expression and/or function of 14-3-3 zeta, selecting a candidate substance determined to modulate the expression and/or function of 14-3-3 zeta, and making a pharmaceutical composition that includes the selected candidate substance. In addition, methods of treating a subject with a hyperproliferative disease, including making a pharmaceutical agent by the methods set forth herein, and administering the pharmaceutical agent to a subject, are disclosed. The hyperproliferative disease can be cancer, such as breast cancer.
14-3-3 Zeta Over-Expression As A Poor Prognosis Factor, And A Therapeutic Target In Multiple Cancer Types
US Patent:
7316907, Jan 8, 2008
Filed:
Sep 10, 2004
Appl. No.:
10/938387
Inventors:
Dihua Yu - Houston TX, US
Jun Yao - Chestnut Hill MA, US
Christopher L. Neal - Houston TX, US
Wentao Yang - Shanghai, CN
Xiaoyan Zhou - Shanghai, CN
Raphael E. Pollock - Houston TX, US
Mien-Chie Hung - Houston TX, US
Jun Yang - Houston TX, US
Ping Li - Houston TX, US
Nina T. Nguyen - Houston TX, US
Jun Yao - Chestnut Hill MA, US
Christopher L. Neal - Houston TX, US
Wentao Yang - Shanghai, CN
Xiaoyan Zhou - Shanghai, CN
Raphael E. Pollock - Houston TX, US
Mien-Chie Hung - Houston TX, US
Jun Yang - Houston TX, US
Ping Li - Houston TX, US
Nina T. Nguyen - Houston TX, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
G01N 33/53, G01N 33/574
US Classification:
435 71, 435 723
Abstract:
Methods of determining prognosis in a subject with a hyperproliferative disease, including determining expression and/or function of 14-3-3 zeta in the subject, are disclosed. Also disclosed are methods of making a pharmaceutical agent that modulates apoptosis, including the steps of obtaining one or more candidate, testing the one or more candidate substances to determine their ability to modulate the expression and/or function of 14-3-3 zeta, selecting a candidate substance determined to modulate the expression and/or function of 14-3-3 zeta, and making a pharmaceutical composition that includes the selected candidate substance. In addition, methods of treating a subject with a hyperproliferative disease, including making a pharmaceutical agent by the methods set forth herein, and administering the pharmaceutical agent to a subject, are disclosed. The hyperproliferative disease can be cancer, such as breast cancer.
Admin Assitant/Pr At Christopher Philip Ltd
Position:
Admin Assitant/PR at Christopher Philip Ltd
Location:
Houston, Texas Area
Industry:
Cosmetics
Work:
Christopher Philip Ltd
-
Admin Assitant/PR